Pharmacokinetics of 5-fluorouracil following hepatic intra-arterial infusion in a VX2 hepatic metastasis model

Japanese Journal of Clinical Oncology

Volumn 33, Issue 8, 2003, Pages 377-381

  Sadahiro, Sotaro ^a   Suzuki, Toshiyuki ^a   Ishikawa, Kenji ^a   Tanaka, Yoichi ^a   Masuda, Takahisa ^a   Nakamura, Tomoki ^a   Yasuda, Seiei ^a   Makuuchi, Hiroyasu ^a   Murayama, Chieko ^a  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

5 fluorouracil; Hepatic intra arterial infusion; Liver metastasis

Indexed keywords

DRUG METABOLITE; FLUOROURACIL; RNA; THYMIDYLATE SYNTHASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BOLUS INJECTION; CONTINUOUS INFUSION; CONTROLLED STUDY; DNA SYNTHESIS INHIBITION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG INFUSION; DRUG INTERMITTENT THERAPY; DRUG TUMOR LEVEL; ENZYME INHIBITION; HEPATIC ARTERY; LIVER INJURY; LIVER METASTASIS; NONHUMAN; RABBIT;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; COLORECTAL NEOPLASMS; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; FLOXURIDINE; FLUOROURACIL; HEPATIC ARTERY; INFUSIONS, INTRA-ARTERIAL; LIVER NEOPLASMS; RABBITS; TISSUE DISTRIBUTION;

EID: 30844440529     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyg077     Document Type: Article

References (20)

1. Kemeny N, Huang Y, Cohen AM, Shi W, Conti JA, Brennan MF, et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 1999;341:2039-48.
2. Seifert P, Baker LH, Reed ML, Vaitkevicius VK. Comparison of continuously infused 5-FU with bolus injection in treatment of patients with colorectal adenocarcinoma. Cancer 1975;36:123-8.
3. Lokich JJ, Ahlgren JD, Gullo JJ, Philips JA, Fryer JG. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: A Mid-Atlantic Oncology Program study. J Clin Oncol 1989;7:425-32.
4. Hansen RM, Ryan L, Anderson T, Krzywda B, Quebbeman E, Benson A, et al. Phase III study of bolus versus infusion fluorouracil with or without cisplatin in advanced colorectal cancer. J Natl Cancer Inst 1996;88:668-74.
5. Weinerman B, Shah A, Fields A, Cripps IC, Wilson K, McCormick R, et al. Systemic infusion versus bolus chemotherapy with 5-FU in measurable metastatic colorectal cancer. Am J Clin Oncol 1992;15:518-23.
6. The Meta-Analysis Group in Cancer. Toxicity of fluorouracil in patients with advanced colorectal cancer. J Clin Oncol 1998;16:3537-41.
7. Peters GJ, Lankelma J, Kok RM, Noordhuis P, Van Groeningen CJ, Van der Wilt CL, et al. Prolonged retention of high concentrations of 5-FU in human and murine tumors as compared with plasma. Cancer Chemother Pharmacol 1993;31:269-76.
8. Spears CP, Gustavsson BG, Mitchell MS, Spicer D, Berne M, Bernstein L, et al. Thymidylate synthetase inhibition in malignant tumors and normal liver of patients given intravenous 5-FU. Cancer Res 1984;44:4144-50.
9. Peters GJ, Noordhuis P, Komissarov A, Holwerda U, Kok M, Van Laar JA, et al. Quantification of 5-fluorouracil incorporation into RNA of human and murine tumors as measured with a sensitive gas chromatography-mass spectrometry assay. Anal Biochem 1995;231:157-63.
10. Harris BE, Song R, Soong SJ, Diasio RB. Relationship between DPD activity and plasma 5-FU levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-FU by protracted continuous infusion. Cancer Res 1990;50:197-201.
11. Kemeny N, Daly J, Reichman B, Geller N, Botet J, Oderman P. Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. Ann Intern Med 1987;107:459-65.
12. Hohn DC, Stagg RJ, Friedman MA, Hannigan JF, Rayner A, Ignoffo RJ, et al. A randomized trial of continuous intravenous versus hepatic intraarterial fluoxuridine in patients with colorectal cancer metastatic to the liver: The Northern California Oncology Group Trial. J Clin Oncol 1989; 7:1646-54.
13. Martin JK, O'Connell MJ, Wieand HS, Fitzgibbons RJ, Mailliard JA, Rubin J, et al. Intra-arterial floxuridine vs. systemic fluorouracil for hepatic metastases from colorectal cancer. Arch Surg 1990;125:1022-7.
14. Rougier P, Laplanche A, Huguier M, Hay JM, Ollivier JM, Escat J, et al. Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: Long-term results of a prospective randomized trial. J Clin Oncol 1992;10:1112-8.
15. Conway JG, Popp JA, Ji S, Thurman RG. Effect of size on portal circulation of hepatic nodules from carcinogen-treated rats. Cancer Res 1983;43: 3374-8.
16. Arai Y, Inaba Y, Takeuchi Y, Ariyoshi Y. Intermittent hepatic arterial infusion of high-dose 5FU on a weekly schedule for liver metastases from colorectal cancer. Cancer Chemother Pharmacol 1997;40:526-30.
17. Inaba M, Mitsuhashi J, Ozawa S. Kinetic analysis of 5-FU action against various cancer cells. Jpn J Cancer Res 1990;81:1039-44.
18. Van der Wilt CL, Pinedo HM, Smid Y, Peters GJ. Elevation of thymidylate synthase following 5-fluorouracil treatment is prevented by the addition of leucovorin in murine colon tumors. Cancer Res 1992;52:4922-8.
19. Inaba M, Naoe, Y, Mitsuhashi, J. Mechanisms for 5-FU resistance in human colon cancer DLD-1 cells. Biol Pharm Bull 1998;21:569-73.
20. Van der Wilt CL, Van Groeningen CJ, Pinedo RM, Smid K, Hoekman K, Meijer S, et al. 5-FU/leucovorin-induced inhibition of thymidylate synthase in normal tissue of mouse and man. J Cancer Res Clin Oncol 1997; 123:595-601.